EUVIMEDEUVIMED entdecken
Crossref

Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

Kelsie Cowman iD, Alexander Miller, Yi Guo, Mei H Chang, Terrence McSweeney, Hongkai Bao, Roxanne Simpson, Claire Braithwaite, Evans Sunu, Theary Ros, Maria Rodriguez, Eric Laboy und 5 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Kelsie Cowman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Outpatients, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess and compare subsequent hospital admissions within 30 days for patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir.

Methods

We conducted a retrospective review of 3207 high-risk, non-hospitalized adult COVID-19 patients who received a prescription for molnupiravir (n = 209) or nirmatrelvir/ritonavir (n = 2998) at an academic medical centre in New York City from April to December 2022. Variables including age, vaccination status, high-risk conditions and demographic factors were pulled from the electronic medical record. We used multivariable logistic regression to adjust for potential confounding variables.

Results

All-cause 30 day hospitalization was not significantly different between patients who received nirmatrelvir/ritonavir compared with molnupiravir (1.4% versus 1.9%, P value = 0.55). The association between COVID-related hospitalization and medication was also not significant (0.7%versus 0.5%, P value = 0.99). Patients who received molnupiravir were more likely to have more underlying high-risk conditions. After adjusting for potential confounders, the odds of all-cause hospitalizations were not significantly different between patients who received nirmatrelvir/ritonavir compared with molnupiravir (OR = 1.16, 95% CI: 0.4–3.3, P value = 0.79).

Conclusions

These data provide additional evidence to support molnupiravir as a suitable alternative when other COVID-19 antivirals cannot be given.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OutpatientsCOVID-19AdultHumansRitonavirCOVID-19 Drug TreatmentPrescriptionsAntiviral AgentsLactamsLeucineNitrilesProlineCytidineHydroxylamines

Substanzen

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProlinemolnupiravirCytidineHydroxylamines

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Network Performance Group, Montefiore Health System, Bronx, NY, USA.
  • Department of Pharmacy, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Department of Nursing, Montefiore Medical Center, Bronx, NY, USA.
  • Faculty Practice Group, Montefiore Health System, Bronx, NY, USA.

ORCID-Profile: Kelsie Cowman

Zitieren

APA

Cowman, K., Miller, A., Guo, Y., Chang, M. H., McSweeney, T., Bao, H., Simpson, R., Braithwaite, C., Sunu, E., Ros, T., Rodriguez, M., Laboy, E., Bard, L., Alsina, L., Cintron, A., Andrews, E., & Nori, P. (2023). Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad154

Vancouver

Cowman K, Miller A, Guo Y, Chang MH, McSweeney T, Bao H, et al. Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad154

BibTeX
@article{Cowman2023,
  author = {Cowman, Kelsie and Miller, Alexander and Guo, Yi and Chang, Mei H and McSweeney, Terrence and Bao, Hongkai and Simpson, Roxanne and Braithwaite, Claire and Sunu, Evans and Ros, Theary and Rodriguez, Maria and Laboy, Eric and Bard, Linda and Alsina, Leslie and Cintron, Angelica and Andrews, Erin and Nori, Priya},
  title = {Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad154}
}
Kostenlos starten →